BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx reported Q1 2026 revenue of $0.5 million, driven by royalties from APHEXDA sales, and a net loss of $2.6 million. The company highlighted a key milestone: the first patient was dosed in the Phase 1/2a clinical trial for GLIX1 in glioblastoma, with two additional abstracts accepted for ASCO.
Key figures
- Eps
- 0
- Revenue
- 477000
- Revenue Yoy
- 87%
- Net loss
- 2588000
- Rd expenses
- 2528000
- Apexda sales
- 2700000
- Operating loss
- 3004000
- Royalty revenue
- 477000
- G and a expenses
- 858000
- Cash and equivalents
- 17400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.